NRG/RTOG 1122: phase II double-blinded, placebo-controlled study of bevacizumab with/without trebananib in patients with recurrent glioblastoma or gliosarcoma

BACKGROUND: Targeting vascular endothelial growth factor (VEGF) alone does not improve overall survival in recurrent glioblastoma (rGBM). The angiopoiein (Ang)-TIE2 system may play a role in tumor survival under VEGF inhibition. We conducted a phase II, double-blinded, placebo-controlled trial of be...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer
Main Authors: Lee, Eudocia Q, Zhang, Peixin, Wen, Patrick Y, Gerstner, Elizabeth R, Reardon, David A, Aldape, Kenneth D, deGroot, John F, Pan, Edward, Raizer, Jeffrey J, Kim, Lyndon J, Chmura, Steven J, Robins, H Ian, Connelly, Jennifer M, Battiste, James D, Villano, John L, Wagle, Naveed, Merrell, Ryan T, Wendland, Merideth M, Mehta, Minesh P
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7245544/
https://ncbi.nlm.nih.gov/pubmed/32154928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32811
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker